References
- Lilja H., Christensson A., Dahlén U., Matikainen M‐T., Nilsson O., Pettersson K. Prostate‐specific antigen in serum occurs predominantly in complex with α1‐antichymotrypsin. Clin Chem 1991; 37: 1618–25
- Noldus J., Chen Z., Stamey T. A. Isolation and characterization of free form prostate specific antigen (f‐PSA) in sera of men with prostate cancer. J Urol 1997; 158: 1606–9
- Stenman U. H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate‐specific antigen and α1‐antichymotrypsin is the major form of prostate‐specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6
- Zhang W. M., Leinonen J., Kalkkinen N., Dowell B., Stenman U. H. Purification and characterization of different molecular forms of prostate‐specific antigen in human seminal fluid. Clin Chem 1995; 41: 1567–73
- Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate‐specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755–63
- Christensson A., Lilja H. Complex formation between protein C inhibitor and prostate‐specific antigen in vitro and in human semen. Eur J Biochem 1994; 220: 45–53
- Zhang W. M., Finne P., Leinonen J., Vesalainen S., Nordling S., Rannikko S., et al. Characterization and immunological determination of the complex between prostate‐specific antigen and α2 macroglobulin. Clin Chem 1998; 44: 2471–9
- Otto A., Bär J., Birkenmeier G. Prostate‐specific antigen forms complexes with human α2‐macroglobulin and binds to the α2‐macroglobulin receptor/LDL receptor‐related protein. J Urol 1998; 159: 297–303
- Leinonen J., Zhang W. M., Stenamn U. H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099–103
- Honda S. A. A., Goldstein A. P., Morita T., Sugiyama C., Cody L., Rios C. N., et al. Prostate‐specific antigen concentrations in serum in acute illnesses. Clin Chem 1996; 42: 1785–8
- Lennard T. W. J., Shenton B. K., Borzotta A., Donnelly P. K., White M., Gerrie L. M., et al. The influence of surgical operations on components of the human immune system. Br J Surg 1985; 72: 771–6
- Meyer A., Jung K., Lein M., Rudolph B., Schnorr D., Loening S. A. Factors influencing the ratio of free to total prostate‐specific antigen in serum. Int J Cancer 1997; 74: 630–6
- Kotyza J. Proteases and antiproteases in health and disease a review – IV. Alpha‐2‐macroglobulin. Biomark Environ 2002; 5: 1–13
- Lilja H., Haese A., Björk T., Friedrich M. G., Piironen T., Pettersson K., et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999; 162: 2029–35
- Zhang W. M., Finne P., Leinonen J., Salo J., Stenman U‐H. Determination of prostate‐specific antigen complexed to alpha2‐macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000; 56: 267–72
- Brandle E., Hautmann O., Bachem M., Kleinschmidt K., Gottfried H. W., Grünert A., et al. Serum half‐life time determination of free and total prostate‐specific antigen following radical prostatectomy – a critical assessment. Urology 1999; 53: 722–30
- Kao P. C., Shiesh S‐C., Wu T‐J. Serum C‐reactive protein as a marker for wellness assessment. Ann Clin Lab Sci 2006; 36: 63–9